This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study designs and other criteria for inclusion in the review
Not reported.
Sources searched to identify primary studies
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
A total of 10 studies were included in th review.
Methods of combining primary studies
Investigation of differences between primary studies
Not reported. The authors acknowledged that there was tremendous variability in the reported incidence of immunity and infection in adults. To tackle this problem, when feasible, values reported in the literature were confirmed by taking small random samples from the study institution's data.
Results of the review
The outcome values (range, representing best-case and worst-case scenarios) for the variables obtained from the literature were as follows: natural immunity, 90% (32 -93%); annual varicella exposure, 15% (2 -18%); varicella infection after exposure, 35% (18 -80%); vaccine efficacy, 70% (70 -96%); vaccine-induced vesicular rash, 4% (4 -6%).
Methods used to derive estimates of effectiveness
Assumptions made by the author.
Estimates of effectiveness and key assumptions
It was assumed that 5% of the employees eligible to receive the vaccine (VZV susceptible or potentially susceptible) would not receive it because of contraindication or non-compliance. The measure of benefits was the number of patients prevented from being exposed to VZV and the number of employees prevented from contracting VZV infection in a cohort of 10,000 employees potentially susceptible to VZV.
Measure of benefits used in the economic analysis

Direct costs
Costs were not discounted due to the short time frame of the cost analysis. Some cost items were reported separately. Cost analysis covered the costs of pharmaceuticals (medications for managing patient exposures and employee infection), laboratory tests, vaccines, and personnel (health employees, infection control employees, furloughed employees, and replacement workers for furloughed employees). The perspective adopted in the cost analysis was that of the study institution, which both paid for and provided the preventive programmes. The values used in the model were the most frequently reported values or the values agreed upon by the institution's expert as the reference values. The least and most favourable values were combined to estimate the worst-best case scenarios. The price year was not reported. The consequences and costs of a false-positive antibody test were negligible and therefore were excluded. The impact of vaccination on costs associated with herpes zoster virus infection was not included.
Indirect Costs
Indirect costs were not included.
Currency
US dollars ($).
Sensitivity analysis
Analyses of extremes were performed by considering worst-best case scenarios on effectiveness and cost variables.
Estimated benefits used in the economic analysis
The reduction in employee infections and patient exposures was the same for both a screen, then vaccinate strategy and a vaccinate-all strategy. Either strategy reduced employee infections by approximately 35 (range: 10 -146) per 10,000 employees. The number of patient exposures reduced by vaccination varied only with the proportion of vaccinees directly involved in patient care. The reduction in patient exposures if all employees were vaccinated was approximately 674 (range: 57 -7,285) per 10,000 employees. If all vaccinees could potentially expose patients (the direct care and high-risk groups), about 1,496 patients exposures (range: 192 -12,142) were prevented for every 10,000 employees vaccinated.
Cost results
The cost per patient for the screen only strategy was $75 (range representing best-worst case scenarios: 31 -292) for the all-vaccinate group, $103 (range: 35 -62) for the direct care group, and $143 (range: 39 -1,013) for the high-risk group.
The corresponding costs for the screen and vaccinate strategy were $52 (range: 35 -200) for the all-vaccinate group, $62 (range: 36 -338) for the direct care group and $75 (range: 36 -445) for the high-risk group.
